-- As the science of aging continues to evolve, a growing body of research is turning attention toward senolytics—an emerging class of compounds designed to target and remove so-called “zombie cells” in the body. A newly published article by NMN Labo explores this cutting-edge field, focusing on natural compounds like quercetin and fisetin and their potential role in longevity science.
The article, titled “What Are Senolytics?”, provides an in-depth look at how senescent cells—cells that have stopped dividing but refuse to die—accumulate over time and contribute to chronic inflammation and age-related decline. These dysfunctional cells release harmful molecules that can damage surrounding tissue, a process increasingly linked to conditions such as cardiovascular disease, metabolic disorders, and cognitive decline.
Senolytics aim to address this issue by selectively clearing these cells, allowing the body to maintain healthier cellular function. While the concept is still under active investigation, early findings from laboratory and animal studies suggest that reducing senescent cell burden may improve markers of healthspan.
Natural compounds like quercetin and fisetin have attracted particular interest due to their presence in everyday foods such as apples, onions, and strawberries. Researchers have observed that these flavonoids may influence cellular pathways associated with senescence, although most evidence to date comes from preclinical studies. Human trials are ongoing, and experts emphasize the importance of distinguishing between promising research and confirmed clinical outcomes.
The NMN Labo article also examines how senolytics may complement NAD+ boosting strategies, including NMN supplementation, which is widely studied for its role in cellular energy and repair. By combining approaches that support cellular health with those that potentially remove damaged cells, researchers are working toward a more comprehensive understanding of healthy aging.
Despite the excitement, the article underscores a key point: senolytics are not yet established anti-aging treatments. Regulatory approval for longevity use has not been granted, and further large-scale human studies are needed to determine safety, optimal dosing, and long-term effects.
For readers interested in the science behind this emerging field, the full article offers a balanced perspective—separating evidence-based insights from marketing hype.
Read the full article here: https://nmnlabo.com/blog/what-are-senolytics/
Contact Info:
Name: Laurynas Brazys
Email: Send Email
Organization: Wtock Ventures Ltd.
Website: https://nmnlabo.com/
Release ID: 89188904
If you come across any problems, discrepancies, or concerns related to the content contained within this press release that necessitate action or if a press release requires takedown, we strongly encourage you to reach out without delay by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our committed team will be readily accessible round-the-clock to address your concerns within 8 hours and take appropriate actions to rectify identified issues or support with press release removals. Ensuring accurate and reliable information remains our unwavering commitment.
